The startup is developing biosynthetic microbiome biotherapeutics that are donor-independent and synthesized using a deep-tech approach. This technology generates Live Biotherapeutics Products (LBPs) to enhance the scientific understanding of microorganisms' roles in human health and disease treatment.
Funding
$16.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of producing microbiome therapeutics rely on donor-dependent materials, which introduces variability and potential safety concerns. Traditional methods also lack the precision to target specific microbial imbalances associated with various diseases.
Solution
Human Biome Institute is developing biosynthetic microbiome biotherapeutics using a deep-tech approach to create donor-independent Live Biotherapeutic Products (LBPs). Their drug discovery platform combines in silico computational analysis with in vitro culturomics to identify and isolate specific microbial targets. This technology enables the creation of standardized, high-quality LBPs designed to restore gut microbiota balance and enhance the scientific understanding of microorganisms' roles in human health and disease treatment. The company's preparations, including Mbiotix HBI and Mbiotix HBI Caps, are used for fecal microbiota transplantation with high rates of success in treating recurrent Clostridioides difficile infections.
Target Audience
The primary target audience includes medical professionals, medical facilities, and medical practices seeking advanced biotherapeutic agents for treating gut microbiota-related conditions, particularly recurrent Clostridioides difficile infections.
Features
- Donor-independent production of Live Biotherapeutic Products (LBPs)
- Advanced culturomics laboratory for cultivation of difficult-to-culture microbes
- High-throughput genetic, phenotypic, and immunological analyses
- Anaerobic manufacturing facility for safe and bacteria-sparing production
- Mbiotix HBI: Donor-derived fecal microbiota suspension for administration via various methods (intraduodenal, intragastric, intrajejunal tubes, gastroscope, colonoscope, PEG, rectal enema)
- Mbiotix HBI Caps: Donor-derived capsules with a double shell (acid-resistant and enteric) for oral administration, released at the ileocecal area
- Rigorous three-step donor selection process with extensive health questionnaires and testing
- Sample tracking system with unique codes for tracing preparation history
- Quality assurance system operating under GMP conditions